Lorenza Rimassa
@lorenzarimassa.bsky.social
Associate Professor of Medical Oncology at HUNIMED, GI cancer specialist with research interest in #livercancer, #HCC, #biliarytractcancer, #cholangiocarcinoma
JulieHeimbach discusses #livertransplant for patients with intrahepatic or perihilar #cholangiocarcinoma #CCA at the Advances in Hepatology Symposium in Berlin #FalkFoundation
October 25, 2025 at 10:03 AM
JulieHeimbach discusses #livertransplant for patients with intrahepatic or perihilar #cholangiocarcinoma #CCA at the Advances in Hepatology Symposium in Berlin #FalkFoundation
@myesmo.bsky.social is where everything began, my first international oral presentation as a resident in medical oncology, my first international role as chair, discussant, invited speaker.
I will always be grateful to #ESMO!
#myESMOStory
#ESMO25
#ESMOAmbassadors
I will always be grateful to #ESMO!
#myESMOStory
#ESMO25
#ESMOAmbassadors
October 20, 2025 at 9:53 AM
@myesmo.bsky.social is where everything began, my first international oral presentation as a resident in medical oncology, my first international role as chair, discussant, invited speaker.
I will always be grateful to #ESMO!
#myESMOStory
#ESMO25
#ESMOAmbassadors
I will always be grateful to #ESMO!
#myESMOStory
#ESMO25
#ESMOAmbassadors
It’s great to see a friend and colleague growing within @myesmo.bsky.social!
#ESMO25
#myESMOStory
#ESMOAmbassadors
#ESMO25
#myESMOStory
#ESMOAmbassadors
October 20, 2025 at 9:45 AM
It’s great to see a friend and colleague growing within @myesmo.bsky.social!
#ESMO25
#myESMOStory
#ESMOAmbassadors
#ESMO25
#myESMOStory
#ESMOAmbassadors
James Harding presents phase 1 data showing a manageable safety profile and promising efficacy in advanced #PDAC at #ESMO25 #ESMOAmbassadors @myesmo.bsky.social
October 20, 2025 at 7:49 AM
James Harding presents phase 1 data showing a manageable safety profile and promising efficacy in advanced #PDAC at #ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Do-Youn Oh discusses abstracts on #biliary tract cancer #BTC #CCA orally presented at #ESMO25 #ESMOAmbassadors @myesmo.bsky.social
October 20, 2025 at 7:44 AM
Do-Youn Oh discusses abstracts on #biliary tract cancer #BTC #CCA orally presented at #ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Michele Reni presents novel findings from the #CASSANDRA phase 3 study of perioperative treatment in #PDAC
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
October 20, 2025 at 7:34 AM
Michele Reni presents novel findings from the #CASSANDRA phase 3 study of perioperative treatment in #PDAC
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
IMMUNOBIL phase 2 study of immunotherapy #STRIDE for patients with previously treated advanced #BTC #CCA. Negative study but a subgroup of patients seem to benefit, we need biomarkers.
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
October 20, 2025 at 7:26 AM
IMMUNOBIL phase 2 study of immunotherapy #STRIDE for patients with previously treated advanced #BTC #CCA. Negative study but a subgroup of patients seem to benefit, we need biomarkers.
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Phase 2-3 ZSAB-neoGOLP trial of #neoadjuvant GOLP regimen for resectable i#CCA with high-risk features for recurrence. A positive interim analysis, but not a standard regimen. Novel approaches are needed.
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
October 20, 2025 at 7:18 AM
Phase 2-3 ZSAB-neoGOLP trial of #neoadjuvant GOLP regimen for resectable i#CCA with high-risk features for recurrence. A positive interim analysis, but not a standard regimen. Novel approaches are needed.
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Milind Javle presents the results of #tinengotinib in patients with #CCA #BTC and #FGFR2 gene fusions previously treated with other FGFR inhibitors at #ESMO25
#ESMOAmbassadors @myesmo.bsky.social
#ESMOAmbassadors @myesmo.bsky.social
October 20, 2025 at 7:13 AM
Milind Javle presents the results of #tinengotinib in patients with #CCA #BTC and #FGFR2 gene fusions previously treated with other FGFR inhibitors at #ESMO25
#ESMOAmbassadors @myesmo.bsky.social
#ESMOAmbassadors @myesmo.bsky.social
@arndtvogel.bsky.social discusses #ABC-HCC and #TALENTop studies and puts them into the context.
Positive studies, potential novel strategies, still open questions.
Key message, #MDT is key in the management of patients with #HCC.
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Positive studies, potential novel strategies, still open questions.
Key message, #MDT is key in the management of patients with #HCC.
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
October 20, 2025 at 6:56 AM
@arndtvogel.bsky.social discusses #ABC-HCC and #TALENTop studies and puts them into the context.
Positive studies, potential novel strategies, still open questions.
Key message, #MDT is key in the management of patients with #HCC.
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Positive studies, potential novel strategies, still open questions.
Key message, #MDT is key in the management of patients with #HCC.
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Hui-Chuan Sun presents the #TALENTop phase 3 study of atezolizumab-bevacizumab followed by surgery in locally advanced #HCC.
Positive study, #MDT discussion is key!
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Positive study, #MDT discussion is key!
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
October 20, 2025 at 6:49 AM
Hui-Chuan Sun presents the #TALENTop phase 3 study of atezolizumab-bevacizumab followed by surgery in locally advanced #HCC.
Positive study, #MDT discussion is key!
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Positive study, #MDT discussion is key!
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Peter Galle presents ABC-HCC, academic study of atezolizumab-bevacizumab vs TACE for intermediate stage #HCC.
Improved time to failure of treatment strategy with #systemic therapy.
Positive study, potential novel approach for #intermediate HCC
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Improved time to failure of treatment strategy with #systemic therapy.
Positive study, potential novel approach for #intermediate HCC
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
October 20, 2025 at 6:41 AM
Peter Galle presents ABC-HCC, academic study of atezolizumab-bevacizumab vs TACE for intermediate stage #HCC.
Improved time to failure of treatment strategy with #systemic therapy.
Positive study, potential novel approach for #intermediate HCC
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Improved time to failure of treatment strategy with #systemic therapy.
Positive study, potential novel approach for #intermediate HCC
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Stephen L. Chan discusses #CARES-009 and #SKYSCRAPER-14 phase 3 studies in #HCC at #ESMO25
#ESMOAmbassadors @myesmo.bsky.social
#ESMOAmbassadors @myesmo.bsky.social
October 19, 2025 at 9:40 AM
Stephen L. Chan discusses #CARES-009 and #SKYSCRAPER-14 phase 3 studies in #HCC at #ESMO25
#ESMOAmbassadors @myesmo.bsky.social
#ESMOAmbassadors @myesmo.bsky.social
CARES-009 phase 3 study of perioperative camrelizumab and rivoceranib for #HCC
#ESMO25 #ESMOAmbassadors
@myesmo.bsky.social
#ESMO25 #ESMOAmbassadors
@myesmo.bsky.social
October 19, 2025 at 9:22 AM
CARES-009 phase 3 study of perioperative camrelizumab and rivoceranib for #HCC
#ESMO25 #ESMOAmbassadors
@myesmo.bsky.social
#ESMO25 #ESMOAmbassadors
@myesmo.bsky.social
Richard Finn presents the results of phase 3 IMbrave152/SkYSCRAPER-14 study at #ESMO25
Anti-TIGIT tiragolumab does not add benefit to atezolizumab-bevacizumab for patients with advanced #HCC
#ESMOAmbassadors @myesmo.bsky.social
Anti-TIGIT tiragolumab does not add benefit to atezolizumab-bevacizumab for patients with advanced #HCC
#ESMOAmbassadors @myesmo.bsky.social
October 19, 2025 at 9:09 AM
Richard Finn presents the results of phase 3 IMbrave152/SkYSCRAPER-14 study at #ESMO25
Anti-TIGIT tiragolumab does not add benefit to atezolizumab-bevacizumab for patients with advanced #HCC
#ESMOAmbassadors @myesmo.bsky.social
Anti-TIGIT tiragolumab does not add benefit to atezolizumab-bevacizumab for patients with advanced #HCC
#ESMOAmbassadors @myesmo.bsky.social
HRS-4642 combined with chemo in advanced #KRAS-G12D mutant #PDAC
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
October 19, 2025 at 8:40 AM
HRS-4642 combined with chemo in advanced #KRAS-G12D mutant #PDAC
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
#ESMO25 #ESMOAmbassadors @myesmo.bsky.social
Breaking the boundaries in pancreatic cancer #PDAC #surveillance #risk #liquidbiopsy #ctDNA #KRAS #noveltherapies
#ESMO25 #ESMOAmbassadors
@benwestphalen.bsky.social @myesmo.bsky.social
#ESMO25 #ESMOAmbassadors
@benwestphalen.bsky.social @myesmo.bsky.social
October 18, 2025 at 3:24 PM
Breaking the boundaries in pancreatic cancer #PDAC #surveillance #risk #liquidbiopsy #ctDNA #KRAS #noveltherapies
#ESMO25 #ESMOAmbassadors
@benwestphalen.bsky.social @myesmo.bsky.social
#ESMO25 #ESMOAmbassadors
@benwestphalen.bsky.social @myesmo.bsky.social
Matteo Simonelli presents the results for MK-1084 monotherapy in patients with #KRAS #G12C-mutated advanced solid tumors enrolled in the #phase1 KANDLELIT-001 study at #ESMO25 #ESMOAmbassadors @myesmo.bsky.social
October 17, 2025 at 3:10 PM
Matteo Simonelli presents the results for MK-1084 monotherapy in patients with #KRAS #G12C-mutated advanced solid tumors enrolled in the #phase1 KANDLELIT-001 study at #ESMO25 #ESMOAmbassadors @myesmo.bsky.social
#TeresaMacarulla nicely summarizes new data on #HPB cancers presented at #ESMOGI2025 #HCC #BTC #CCA #PDAC #ESMOAmbassadors @myesmo.bsky.social Post n.2
July 5, 2025 at 10:14 AM
#TeresaMacarulla nicely summarizes new data on #HPB cancers presented at #ESMOGI2025 #HCC #BTC #CCA #PDAC #ESMOAmbassadors @myesmo.bsky.social Post n.2
#TeresaMacarulla nicely summarizes new data on #HPB cancers presented at #ESMOGI2025 #HCC #BTC #CCA #PDAC #ESMOAmbassadors @myesmo.bsky.social
July 5, 2025 at 10:11 AM
#TeresaMacarulla nicely summarizes new data on #HPB cancers presented at #ESMOGI2025 #HCC #BTC #CCA #PDAC #ESMOAmbassadors @myesmo.bsky.social
@myesmo.bsky.social updated guidelines and living guidelines on #GI cancers presented by #MichelDucreux at #ESMOGI2025 #ESMOAmbassadors
July 5, 2025 at 9:44 AM
@myesmo.bsky.social updated guidelines and living guidelines on #GI cancers presented by #MichelDucreux at #ESMOGI2025 #ESMOAmbassadors
Patient’s perspective presented by #ZoranaMaravic @digestivecancerseu.bsky.social at #ESMOGI2025 #ESMOAmbassadors @myesmo.bsky.social
July 5, 2025 at 9:23 AM
Patient’s perspective presented by #ZoranaMaravic @digestivecancerseu.bsky.social at #ESMOGI2025 #ESMOAmbassadors @myesmo.bsky.social
Prof Tabernero lecture on lessons learned from #GI translational research and the path forward at #ESMOGI25 @myesmo.bsky.social #ESMOAmbassadors
July 5, 2025 at 9:05 AM
Prof Tabernero lecture on lessons learned from #GI translational research and the path forward at #ESMOGI25 @myesmo.bsky.social #ESMOAmbassadors
Preliminary efficacy results of the phase 3b ProvIDHe study of #ivosidenib in patients with #IDH1- mutated cholangiocarcinoma #CCA at #ESMOGI25 @myesmo.bsky.social #ESMOAmbassadors
July 5, 2025 at 7:42 AM
Preliminary efficacy results of the phase 3b ProvIDHe study of #ivosidenib in patients with #IDH1- mutated cholangiocarcinoma #CCA at #ESMOGI25 @myesmo.bsky.social #ESMOAmbassadors